An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus.

Abstract

INTRODUCTION Type 2 diabetes mellitus (T2DM) is a growing and serious global health problem. Pharmacological inhibition of the sodium-glucose cotransporter-2 (SGLT2; SLC5A2) increases urinary glucose excretion, decreasing plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 have recently become available for clinical therapy of… (More)
DOI: 10.1517/13543776.2015.1076392

Topics

Cite this paper

@article{Jiang2015AnEO, title={An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus.}, author={Meiyan Jiang and Peter S Steyger}, journal={Expert opinion on therapeutic patents}, year={2015}, volume={25 11}, pages={1349-52} }